Treatment of Type 1 Diabetes Before and After Expression of Predisposition Markers

The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for the effective endocytic presentation of immunosuppressive factors for the down regulation of diabetogenic T cells for the treatment of type 1 diabetes.

Patents:
US 20,100,278,823

Inventor(s): ZAGHOUANI HABIB [US]; GREGG RANDAL KEITH [US]

Type of Offer: Licensing